Obesity drugs in clinical development.
Halford. Jason C G JC
Key Findings
- AOD‑9604 is listed as a human growth hormone fragment aimed at increasing fat breakdown.
- Most anti‑obesity candidates, including AOD‑9604, are still in early clinical stages.
- Only rimonabant has completed Phase III trials among the drugs discussed.
Practical Outcomes
- For biohackers, the main takeaway is that AOD‑9604 is still experimental and not yet proven for real‑world use. There are no dosage recommendations or safety data, so it should be approached cautiously and not added to protocols until more robust trial results become available.
Summary
The article reviews several anti‑obesity drugs that are still being tested, including AOD‑9604, a fragment of human growth hormone that is said to help break down fat. It notes that most of these compounds are still early in trials, with only rimonabant having finished Phase III. No new data on dosing or effectiveness of AOD‑9604 are provided.
Abstract
A number of anti-obesity drugs are currently undergoing clinical development. These include: (i) centrally-acting drugs, such as the noradrenergic and dopaminergic reuptake inhibitor radafaxine, the endocannabinoid antagonist rimonabant, the selective serotonin 5-HT2c agonist APD-356, and oleoyl-estrone; (ii) drugs that target peripheral episodic satiety signals, such as glucagon-like peptide-1 (exenatide, exenatide-LAR and liraglutide), peptide YY (intranasal PYY3-36 and AC-162325) and amylin (pramlintide); (iii) drugs that block fat absorption, such as the novel lipase inhibitors cetilistat and GT-389255; and (iv) a human growth hormone fragment (AOD-9604) that increases adipose tissue breakdown. Of these, only rimonabant has got as far as completing phase III clinical trials. This review will provide an overview of the most prominent drugs currently undergoing clinical development as potential anti-obesity therapies.
Study Information
pubmed
2006